<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OXACILLIN- oxacillin sodiumÂ injection, powder, for solutionÂ </strong><br>Sagent Pharmaceuticals<br></p></div>
<h1>Oxacillin for Injection, USP<br>(For IV or IM Injection)
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">SAGENTâ„¢<br>Rx only
</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Oxacillin for Injection and other antibacterial drugs, Oxacillin for Injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Oxacillin for Injection, USP is a semisynthetic penicillin antibiotic derived from the penicillin nucleus, 6-amino-penicillanic acid. It is resistant to inactivation by the enzyme penicillinase (beta-lactamase). It is the sodium salt in parenteral dosage form for intramuscular or intravenous use. Each vial of Oxacillin for Injection, USP contains oxacillin sodium monohydrate equivalent to 1 gram or 2 grams of oxacillin. The sodium content is 63.77 mg [2.77 mEq] per gram oxacillin. The product is buffered with 20 mg dibasic sodium phosphate per gram oxacillin. Oxacillin for Injection, USP is a white to off-white powder filled in clear glass vials. Dilute solutions are essentially clear and colorless to yellow.
</p>
<p><span class="Bold">OXACILLIN SODIUM</span></p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f3bee4d7-82d8-4e2d-8fc8-4446e6fbf999&amp;name=oxa03-0000-01.jpg">
</div>
<p>4-Thia-1-azabicyclo [3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[(5-methyl-3-phenyl-4-isoxazolyl) carbonyl] amino]-7-oxo-monosodium salt, monohydrate, [2S(2Î±,5Î±,6Î²)].
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Slow I.V. administration of 500 mg gives a peak serum level of 43 mcg/mL after 5 minutes with a half-life of 20-30 minutes.
</p>
<p>The penicillinase-resistant penicillins bind to serum protein, mainly albumin. The degree of protein binding reported for oxacillin is 94.2% Â± 2.1%. Reported values vary with the method of study and the investigator.
</p>
<p>The penicillinase-resistant penicillins vary in the extent to which they are distributed in the body fluids. With normal doses, insignificant concentrations are found in the cerebrospinal fluid and aqueous humor. All the drugs in this class are found in therapeutic concentrations in the pleural, bile, and amniotic fluids.
</p>
<p>The penicillinase-resistant penicillins are rapidly excreted primarily as unchanged drug in the urine by glomerular filtration and active tubular secretion. The elimination half-life for oxacillin is about 0.5 hours. Nonrenal elimination includes hepatic inactivation and excretion in bile.
</p>
<p>Probenecid blocks the renal tubular secretion of penicillins. Therefore, the concurrent administration of probenecid prolongs the elimination of oxacillin and, consequently, increases the serum concentration.
</p>
<p>Intramuscular injections give peak serum levels 30 minutes after injection. A 250 mg dose gives a level of 5.3 mcg/mL while a 500 mg dose peaks at 10.9 mcg/mL. Intravenous injection gives a peak about 5 minutes after the injection is completed. Slow IV dosing with 500 mg gives a 5 minute peak of 43 mcg/mL with a half-life of 20 to 30 minutes.
</p>
<div class="Section" data-sectionCode="49489-8">
<a name="s4"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology
</h2>
<p class="First">Penicillinase-resistant penicillins exert a bactericidal action against penicillin susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall.
</p>
<p>The drugs in this class are highly resistant to inactivation by staphylococcal penicillinase and are active against penicillinase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Staphylococcus aureus.</span> The penicillinase-resistant penicillins are active <span class="Italics">in vitro</span> against a variety of other bacteria.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Test Methods
</h2>
<p class="First">When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-3.2.1"></a><p></p>
<h3>Dilution Techniques
</h3>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on dilution method <span class="Sup">1, 2</span> (broth, agar or microdilution) or equivalent using standardized inoculum and concentrations of oxacillin. The MIC values should be interpreted according to the criteria in <a href="#t1">Table 1</a>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-3.2.2"></a><p></p>
<h3>Diffusion Techniques
</h3>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2,3</span> requires the use of standardized inoculum concentrations. It has been determined that the most accurate method to test the susceptibility of microorganisms to penicillinase-resistant penicillins, including oxacillin, by disk diffusion is achieved using disks impregnated with 30 mcg cefoxitin. Interpretation involves correlation of the diameter obtained in the cefoxitin disk test with the MIC for oxacillin.<span class="Sup">2,4,5</span> Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 microgram cefoxitin disk should be interpreted according to the following criteria in <a href="#t1">Table 1</a>.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Susceptibility Test Interpretive Criteria for Oxacillin
</span></caption>
<col align="left" width="25.000%">
<col align="left" width="18.750%">
<col align="left" width="18.750%">
<col align="left" width="18.750%">
<col align="left" width="18.750%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/mL)</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Cefoxitin Disk Diffusion Diameters (mm)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="justify" valign="top"><span class="Bold">Pathogen</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">SusceptibleÂ (S)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">ResistantÂ (R)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">SusceptibleÂ (S)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">ResistantÂ (R)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics">Staphylococcus aureus,  S. lugdunensis</span><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¤ 2
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¥ 4
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¥ 22
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¤ 21<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Staphylococci<br>Â  Â  Â  (coagulaseÂ negative)
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¤ 0.25
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¥ 0.5
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¥ 25
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¤ 24<br>
</td>
</tr>
</tbody>
</table>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in blood. A report of â€œResistantâ€? indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-3.2.3"></a><p></p>
<h3>Quality Control
</h3>
<p class="First">Standardized susceptibility test procedures require the use of laboratory control microorganisms to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test. Standard oxacillin powder should provide MIC values provided below. For the diffusion technique, the 30 mcg cefoxitin disk should provide the following zone diameters with the quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2. In Vitro Susceptibility Test Quality Control Ranges for Oxacillin
</span></caption>
<col align="left" width="31.033%">
<col align="left" width="29.967%">
<col align="left" width="39.000%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><span class="Bold">Organism (ATCC #)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Oxacillin MIC range (mcg/mL)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Cefoxitin disk diffusion range (mm)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
<span class="Italics">Staphylococcus aureus</span> (29213)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.12 â€“ 0.5
</td>
<td class="Botrule Rrule" align="center" valign="top">Not applicable
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
<span class="Italics">Staphylococcus aureus</span> (25923)
</td>
<td class="Botrule Rrule" align="center" valign="top">Not applicable
</td>
<td class="Botrule Rrule" align="center" valign="top">23 â€“ 29
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s9"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Oxacillin is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug. (See <span class="Bold"><a href="#s5">Clinical Pharmacology - Susceptibility Test Methods</a></span>).
</p>
<p>Oxacillin may be used to initiate therapy in suspected cases of resistant <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span> prior to the availability of susceptibility test results. Oxacillin should not be used in <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is due to an organism other than a resistant <span class="Italics">Staphylococcus,</span> therapy should not be continued with oxacillin.
</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Oxacillin for Injection, USP and other antibacterial drugs, Oxacillin for Injection, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s10"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">A history of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reaction to any penicillin is a contraindication.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s11"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> with collapse) reactions have occurred in patients receiving penicillin. The incidence of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> in all penicillin-treated patients is between 0.015 and 0.04 percent. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has occurred in approximately 0.002 percent of the patients treated. Although <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> is more frequent following parenteral administration, it has occurred in patients receiving oral penicillins.
</p>
<p>When penicillin therapy is indicated, it should be initiated only after a comprehensive patient drug and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> history has been obtained. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, the drug should be discontinued and the patient should receive supportive treatment, <span class="Italics">e.g.,</span> artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. Individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> may also experience <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> when treated with a cephalosporin.
</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Oxacillin for Injection, USP, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile.</span></p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile,</span> and surgical evaluation should be instituted as clinically indicated.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s12"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s13"></a><a name="section-7.1"></a><p></p>
<h2>General
</h2>
<p class="First">Oxacillin should generally not be administered to patients with a history of sensitivity to any penicillin. Penicillin should be used with caution in individuals with histories of significant allergies and/or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Whenever <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> occur, penicillin should be withdrawn unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to penicillin therapy. The use of antibiotics may result in overgrowth of nonsusceptible organisms. If new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacteria or fungi occur, the drug should be discontinued and appropriate measures taken.
</p>
<p>Prescribing Oxacillin for Injection, USP in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s14"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">Patients should be counseled that antibacterial drugs including Oxacillin for Injection, USP should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> <span class="Italics">(e.g.,</span> the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Oxacillin for Injection, USP is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Oxacillin for Injection, USP or other antibacterial drugs in the future.
</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s15"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests
</h2>
<p class="First">Bacteriologic studies to determine the causative organisms and their susceptibility to oxacillin should be performed. (See <span class="Bold"><a href="#s4">Clinical Pharmacology-Microbiology</a></span>). In the treatment of suspected <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span>, therapy should be changed to another active agent if culture tests fail to demonstrate the presence of staphylococci. Periodic assessment of organ system function including renal, hepatic, and hematopoietic should be made during prolonged therapy with oxacillin.
</p>
<p>Blood cultures, white blood cell, and differential cell counts should be obtained prior to initiation of therapy and at least weekly during therapy with oxacillin.
</p>
<p>Periodic urinalysis, blood urea nitrogen, and creatinine determinations should be performed during therapy with oxacillin and dosage alterations should be considered if these values become elevated. If any impairment of renal function is suspected or known to exist, a reduction in the total dosage should be considered and blood levels monitored to avoid possible neurotoxic reactions.
</p>
<p>AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) and ALT (SGPT) values should be obtained periodically during therapy to monitor for possible liver function abnormalities.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s16"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions
</h2>
<p class="First">Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
</p>
<p>Oxacillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s17"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">No long-term animal studies have been conducted with these drugs. Studies on reproduction (nafcillin) in rats and rabbits reveal no fetal or maternal abnormalities before conception and continuously through weaning (one generation).
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s18"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s19"></a><a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects
</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-7.6.1.1"></a><p></p>
<h4>Pregnancy Category B
</h4>
<p class="First">Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to the penicillinase-resistant penicillins. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate or well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s21"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">Penicillins are excreted in human milk. Caution should be exercised when penicillins are administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s22"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Because of incompletely developed renal function in pediatric patients, oxacillin may not be completely excreted, with abnormally high blood levels resulting. Frequent blood levels are advisable in this group with dosage adjustments when necessary. All pediatric patients treated with penicillins should be monitored closely for clinical and laboratory evidence of toxic or adverse effects. Safety and effectiveness in pediatric patients have not been established.
</p>
<p>The potential for toxic effects in pediatric patients from chemicals that may leach from the single dose premixed intravenous preparation in plastic containers has not been evaluated.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s23"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use
</h2>
<p class="First">Clinical studies of Oxacillin for Injection did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
</p>
<p>Oxacillin for Injection contains 63.77 mg (2.77 mEq) of sodium per gram. At the usual recommended doses, patients would receive between 63.77 and 382.62 mg/day (2.77 and 16.62 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s24"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-8.1"></a><p></p>
<h2>Body as a Whole
</h2>
<p class="First">The reported incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to penicillin ranges from 0.7 to 10 percent (see <span class="Bold"><a href="#s11">Warnings</a></span>). Sensitization is usually the result of treatment but some individuals have had immediate reactions when first treated. In such cases, it is thought that the patients may have had prior exposure to the drug via trace amounts present in milk and vaccines.
</p>
<p>Two types of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to penicillins are noted clinically, immediate and delayed.
</p>
<p>Immediate reactions usually occur within 20 minutes of administration and range in severity from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> to <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Such immediate <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> are very rare (see <span class="Bold"><a href="#s11">Warnings</a></span>) and usually occur after parenteral therapy but have occurred in patients receiving oral therapy. Another type of immediate reaction, an accelerated reaction, may occur between 20 minutes and 48 hours after administration and may include <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Although <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occasionally occur, fatality is uncommon.
</p>
<p>Delayed <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to penicillin therapy usually occur after 48 hours and sometimes as late as 2 to 4 weeks after initiation of therapy. Manifestations of this type of reaction include <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like symptoms <span class="Italics">(i.e.,</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>) and various <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, black or hairy tongue, and other symptoms of <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span> may occur, especially during oral penicillin therapy.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-8.2"></a><p></p>
<h2>Nervous System Reactions
</h2>
<p class="First">Neurotoxic reactions similar to those observed with penicillin G may occur with large intravenous doses of oxacillin, especially with patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-8.3"></a><p></p>
<h2>Urogenital Reactions
</h2>
<p class="First">Renal tubular damage and interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> have been associated infrequently with the administration of oxacillin. Manifestations of this reaction may include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-8.4"></a><p></p>
<h2>Gastrointestinal Reactions
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with the use of oxacillin. The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment (see <span class="Bold"><a href="#s11">WARNINGS</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-8.5"></a><p></p>
<h2>Metabolic Reactions
</h2>
<p class="First">Hepatotoxicity, characterized by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, mainly elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> levels, has been associated with the use of oxacillin.
</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals, Inc. at 1-866-625-1618 or FDA at 1-800-FDA-1088 or</span>Â <span class="Bold Underline">www.fda.gov/medwatch.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s30"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">The signs and symptoms of oxacillin overdosage are those described in the <span class="Bold"><a href="#s24">Adverse Reactions</a></span> section. If signs or symptoms occur, discontinue use of the medication, treat symptomatically, and institute appropriate supportive measures.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s31"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">The penicillinase-resistant penicillins are available for oral administration and for intramuscular and intravenous injection. The sodium salts of methicillin, oxacillin, and nafcillin may be administered parenterally and the sodium salts of cloxacillin, dicloxacillin, oxacillin, and nafcillin are available for oral use.
</p>
<p>Bacteriologic studies to determine the causative organisms and their susceptibility to oxacillin should always be performed. Duration of therapy varies with the type of severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> as well as the overall condition of the patient; therefore, it should be determined by the clinical and bacteriological response of the patient. In severe <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span>, therapy with oxacillin should be continued for at least 14 days. Therapy should be continued for at least 48 hours after the patient has become afebrile, asymptomatic, and cultures are negative. Treatment of <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> and <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span> may require a longer duration of therapy.
</p>
<p>Concurrent administration of oxacillin and probenecid increases and prolongs serum penicillin levels. Probenecid decreases the apparent volume of distribution and slows the rate of excretion by competitively inhibiting renal tubular secretion of penicillin. Penicillin-probenecid therapy is generally limited to those <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> where very high serum levels of penicillin are necessary.
</p>
<p>Oral preparations of the penicillinase-resistant penicillins should not be used as initial therapy in serious, life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (see <span class="Bold"><a href="#s13">PRECAUTIONS-General</a></span>). Oral therapy with the penicillinase-resistant penicillins may be used to follow-up the previous use of a parenteral agent as soon as the clinical condition warrants. For intramuscular gluteal injections, care should be taken to avoid sciatic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve injury</span>.
</p>
<p>With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>.
</p>
<a name="t300"></a><table width="100%">
<caption><span>RECOMMENDED DOSAGES FOR OXACILLIN FOR INJECTION, USP
</span></caption>
<col align="left" width="20.950%">
<col align="left" width="25.950%">
<col align="left" width="27.550%">
<col align="left" width="25.550%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Drug</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Adults</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Infants and Children</span><br><span class="Bold">&lt;40 kg (88 lbs)</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Other</span><br><span class="Bold">Recommendations</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">Oxacillin
</td>
<td class="Botrule Rrule" align="center" valign="middle">250 to 500 mg IM or<br>IV every 4 to 6 hours<br>(mild to moderate<br><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>)
</td>
<td class="Botrule Rrule" align="center" valign="middle">50 mg/kg/day IM or<br>IV in equally divided<br>doses every 6 hours<br>(mild to moderate<br><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">Oxacillin
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 gram IM or IV<br>every 4 to 6 hours<br>(severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>)
</td>
<td class="Botrule Rrule" align="center" valign="middle">100 mg/kg/day IM<br>or IV in equally<br>divided doses every<br>4 to 6 hours<br>(severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>)
</td>
<td class="Botrule Rrule" align="center" valign="middle">Premature and<br>Neonates 25 mg/kg/day<br>IM or IV
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-10.1"></a><p></p>
<h2>Directions for Use
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-10.1.1"></a><p></p>
<h3>For Intramuscular Use
</h3>
<p class="First">Use Sterile Water for Injection, USP. Add 5.7 mL to the 1 gram vial and 11.5 mL to the 2 gram vial. Shake well until a clear solution is obtained. After reconstitution, vials will contain 250 mg of active drug per 1.5 mL of solution. The reconstituted solution is stable for 3 days at 70Â°F or for one week under refrigeration (40Â°F).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-10.1.2"></a><p></p>
<h3>For Direct Intravenous Use
</h3>
<p class="First">Use Sterile Water for Injection, USP or Sodium Chloride Injection, USP. Add 10 mL to the 1 gram vial and 20 mL to the 2 gram vial. Withdraw the entire contents and administer slowly over a period of approximately 10 minutes.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-10.1.3"></a><p></p>
<h3>For Administration by Intravenous Drip
</h3>
<p class="First">Reconstitute as directed above (<span class="Bold"><a href="#s34">For Direct Intravenous Use</a></span>) prior to diluting with Intravenous Solution.
</p>
<a name="t301"></a><table width="100%">
<caption><span>STABILITY PERIODS FOR OXACILLIN FOR INJECTION, USP
</span></caption>
<col align="left" width="14.702%">
<col align="left" width="11.764%">
<col align="left" width="10.789%">
<col align="left" width="13.727%">
<col align="left" width="13.727%">
<col align="left" width="14.702%">
<col align="left" width="9.801%">
<col align="left" width="10.789%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Concentration mg/mL</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Sterile</span><br><span class="Bold">Water for</span><br><span class="Bold">Injection</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Sodium Chloride Injection 0.9%</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">M/6 Molar</span><br><span class="Bold">Sodium</span><br><span class="Bold">Lactate</span><br><span class="Bold">Injection</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Dextrose</span><br><span class="Bold">Injection 5%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">5% Dextrose</span><br><span class="Bold">in 0.45%</span><br><span class="Bold">NaCI</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">10%</span><br><span class="Bold">Invert</span><br><span class="Bold">Sugar</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Lactated</span><br><span class="Bold">Ringers</span><br><span class="Bold">Solution</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="8" valign="middle">ROOM TEMPERATURE (25Âº C)
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">10-100
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">10-30
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">24 Hrs
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">24 Hrs
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">0.5-2
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">6 Hrs
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">6 Hrs
</td>
<td class="Botrule Rrule" align="center" valign="middle">6 Hrs
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="8" valign="middle">REFRIGERATION (4Âº C)
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">10-100
</td>
<td class="Botrule Rrule" align="center" valign="middle">7 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle">7 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">10-30
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">4 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 Days
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="8" valign="middle">FROZEN (-15Âº C)
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">50-100
</td>
<td class="Botrule Rrule" align="center" valign="middle">30 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">250/1.5 mL
</td>
<td class="Botrule Rrule" align="center" valign="middle">30 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">100
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">30 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">10-100
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">30 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle">30 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle">30 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle">30 Days
</td>
<td class="Botrule Rrule" align="center" valign="middle">30 Days
</td>
</tr>
</tbody>
</table>
<p>Stability studies on Oxacillin Sodium at concentrations of 0.5 mg/mL and 2 mg/mL in various intravenous solutions listed below indicate the drug will lose less than 10% activity at room temperature (70Â° F) during a 6-hour period.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-10.2"></a><p></p>
<h2>IV Solution
</h2>
<p class="First">5% Dextrose in Normal Saline
</p>
<p>10% D-Fructose in Water
</p>
<p>10% D-Fructose in Normal Saline
</p>
<p>10% Invert Sugar in Normal Saline
</p>
<p>10% Invert Sugar Plus 0.3% Potassium Chloride in Water
</p>
<p>Only those solutions listed above should be used for the intravenous infusion of Oxacillin Sodium. The concentration of the antibiotic should <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> within the range specified. The drug concentration and the rate and volume of the infusion should be adjusted so that the total dose of oxacillin is administered before the drug loses its stability in the solution in use.
</p>
<p>If another agent is used in conjunction with oxacillin therapy, <span class="Bold">it should not be physically mixed</span> with oxacillin but should be administered separately.
</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
</p>
<p>Do not add supplementary medication to Oxacillin for Injection, USP.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s37"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Each vial of Oxacillin for Injection, USP contains oxacillin sodium monohydrate equivalent to 1 gram or 2 grams of oxacillin and is supplied as:
</p>
<table width="100%">
<col align="left" width="20.000%">
<col align="left" width="50.000%">
<col align="left" width="30.000%">
<tbody class="Headless">
<tr class="First">
<td align="justify" valign="top"><span class="Bold">NDC</span></td>
<td align="justify" valign="top"><span class="Bold">Oxacillin for Injection, USP</span></td>
<td align="justify" valign="top"><span class="Bold">Package Factor</span></td>
</tr>
<tr>
<td align="justify" valign="top">25021-146-10
</td>
<td align="justify" valign="top">1 gram Vial
</td>
<td align="justify" valign="top">10 vials per carton
</td>
</tr>
<tr class="Last">
<td align="justify" valign="top">25021-162-24
</td>
<td align="justify" valign="top">2 gram Vial
</td>
<td align="justify" valign="top">10 vials per carton
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="s38"></a><a name="section-11.1"></a><p></p>
<h2>Storage Conditions
</h2>
<p class="First">Store dry powder at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]
</p>
<p><span class="Bold">Sterile, Nonpyrogenic, Preservative-free.<br>The container closure is not made with natural rubber latex.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s39"></a><a name="section-12"></a><p></p>
<h1>REFERENCES
</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Eighth Edition.</span> CLSI Document M07-A8 (ISBN 1-56238-689-1). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2009.
</li>
<li>Clinical and Laboratory Standards Institute. <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement.</span> CLSI Document M100-S21 (ISBN 1-56238-742-1). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA, 2011.
</li>
<li>Clinical and Laboratory Standards Institute. <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-Tenth Edition.</span> CLSI Document M02-A10 (ISBN 1-56238-688-3). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2009.
</li>
<li>Palazzo ICV, Darini ALC. Evaluation of methods for detecting oxacillin resistance in coagulase-negative staphylococci including cefoxitin disc diffusion. FEMS Microbiol Lett 2006;257:299-305.
</li>
<li>Swenson JM, Tenover FC; Cefoxitin Disk Study Group. Results of disk diffusion testing with cefoxitin correlate with presence of mecA in <span class="Italics">Staphylococcus</span> spp. J Clin Microbiol 2005;43:3818-23.
</li>
</ol>
<p class="First">ATCC is a trademark of American Type Culture Collection.
</p>
<p>SAGENTâ„¢
</p>
<p>Mfd. for SAGENT Pharmaceuticals<br>Schaumburg, IL 60195 (USA)<br>Made in India<br>Â©2013 Sagent Pharmaceuticals, Inc.
</p>
<p>Revised: August 2013
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s40"></a><a name="section-13"></a><p></p>
<p class="First">PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ Vial Label</p>
<p>NDC 25021-146-10</p>
<p>Oxacillin For Injection, USP</p>
<p>1 gram per vial</p>
<p>Rx only</p>
<p>Buffered - For IV or IM Use</p>
<div class="Figure">
<a name="f02"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f3bee4d7-82d8-4e2d-8fc8-4446e6fbf999&amp;name=oxa03-0003-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s41"></a><a name="section-14"></a><p></p>
<p class="First">PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ Vial Label</p>
<p>NDC 25021-162-24</p>
<p>Oxacillin For Injection, USP</p>
<p>2 grams per vial</p>
<p>Rx only</p>
<p>Buffered - For IV or IM Use</p>
<div class="Figure">
<a name="f03"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f3bee4d7-82d8-4e2d-8fc8-4446e6fbf999&amp;name=oxa03-0003-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OXACILLINÂ 		
					</strong><br><span class="contentTableReg">oxacillin sodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25021-146</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>oxacillin sodium</strong> (oxacillin) </td>
<td class="formItem">oxacillin</td>
<td class="formItem">1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25021-146-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091246</td>
<td class="formItem">06/01/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OXACILLINÂ 		
					</strong><br><span class="contentTableReg">oxacillin sodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25021-162</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>oxacillin sodium</strong> (oxacillin) </td>
<td class="formItem">oxacillin</td>
<td class="formItem">2Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25021-162-24</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091246</td>
<td class="formItem">06/01/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Sagent Pharmaceuticals
							(796852890)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f6dcf0c3-6966-4ed9-97e4-468a1a4d7fe4</div>
<div>Set id: f3bee4d7-82d8-4e2d-8fc8-4446e6fbf999</div>
<div>Version: 6</div>
<div>Effective Time: 20130801</div>
</div>
</div>Â <div class="DistributorName">Sagent Pharmaceuticals</div></p>
</body></html>
